Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tezenas du Montcel Sophie, Durr Alexandra, Rakowicz Maria, Nanetti Lorenzo, Charles Perrine, Sulek Anna, Mariotti Caterina, Rola Rafal, Schols Ludger, Bauer Peter, Dufaure-Garé Isabelle, Jacobi Heike, Forlani Sylvie, Schmitz-Hübsch Tanja, Filla Alessandro, Timmann Dagmar, van de Warrenburg Bart P, Marelli Cecila, Kang Jun-Suk, Giunti Paola, Cook Arron, Baliko Laszlo, Melegh Béla, Boesch Sylvia, Szymanski Sandra, Berciano José, Infante Jon, Buerk Katrin, Masciullo Marcella, Di Fabio Roberto, Depondt Chantal, Ratka Susanne, Stevanin Giovanni, Klockgether Thomas, Brice Alexis, Golmard Jean-Louis
Аннотация
METHODS: We combined data from two major European cohorts of SCA1, SCA2, SCA3, and SCA6 mutation carriers: 1187 affected individuals from the EUROSCA registry and 123 preclinical individuals from the RISCA cohort. For each SCA genotype, a regression model was fitted using a log-normal distribution for age at onset with the repeat length of the alleles as covariates. From these models, we calculated expected age at onset from birth and conditionally that this age is greater than the current age.
RESULTS: For SCA2 and SCA3 genotypes, the expanded allele was a significant predictor of age at onset (-0.105±0.005 and -0.056±0.003) while for SCA1 and SCA6 genotypes both the size of the expanded and normal alleles were significant (expanded: -0.049±0.002 and -0.090±0.009, respectively; normal: +0.013±0.005 and -0.029±0.010, respectively). According to the model, we indicated the median values (90% critical region) and the expectancy (SD) of the predicted age at onset for each SCA genotype according to the CAG repeat size and current age.
CONCLUSIONS: These estimations can be valuable in clinical and research. However, results need to be confirmed in other independent cohorts and in future longitudinal studies.
CLINICALTRIALSGOV, NUMBER: NCT01037777 and NCT00136630 for the French patients.